Employment status and diabetic outpatient appointment non-attendance in middle to senior working generation with type 2 diabetes: the Japan diabetes outcome intervention trial-2 large‑scale trial 005 (J-DOIT2-LT005).

"Declarations Conflict of interestYasuaki Hayashino received grants from Ono Pharmaceutical Co., Ltd., Grants-in-Aid for Scientific Research, consulting fees from Ono Pharmaceutical Co., Ltd., honoraria from Eli Lilly Japan K.K., Ono Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company, Ltd., Merck & Co., Inc., Sanofi KK., Daiichi Sankyo Company, Ltd., AstraZeneca K.K., Kowa Pharmaceutical Co., Ltd, Boehringer Ingelheim, Novo Nordisk Pharma Ltd., Bayer Pharma, Sumitomo Dainippon Pharma Co., Ltd., and participated on advisory board of Novo Nordisk Pharma Ltd. The remaining authors have no conflicts of interest to declare. Ethics approvalThis study was performed in line with the principles of the Declaration of Helsinki. This study was approved by the Yokohama City University institutional review board. Consent to participate and/or Consent to publishThe requirement for informed consent was waived due to the nature of the study. Data and/or Code availabilityThe data are not publicly available due to them containing information that could compromise research participant privacy/consent. Conflict of interest Yasuaki Hayashino received grants from Ono Pharmaceutical Co., Ltd., Grants-in-Aid for Scientific Research, consulting fees from Ono Pharmaceutical Co., Ltd., honoraria from Eli Lilly Japan K.K., Ono Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company, Ltd., Merck & Co., Inc., Sanofi KK., Daiichi Sankyo Company, Ltd., AstraZeneca K.K., Kowa Pharmaceutical Co., Ltd, Boehringer Ingelheim, Novo Nordisk Pharma Ltd., Bayer Pharma, Sumitomo Dainippon Pharma Co., Ltd., and participated on advisory board of Novo Nordisk Pharma Ltd. The remaining authors have no conflicts of interest to declare."

"Funding This work was supported by grants from the Japan Agency for Medical Research and Development (Practical Research Project for Life-Style related Diseases including CVD and Diabetes), the Ministry of Health, Labour and Welfare of Japan (Strategic Outcomes Research Program for Research on Diabetes; Comprehensive Research on Life-Style Related Diseases, including CVD and Diabetes H25-016), and a grant from the Japan Diabetes Foundation. The funding agencies played no role in the study design, data collection, data analysis, data interpretation, writing of the report, or the decision to submit the article for publication."